These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38296818)

  • 21. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
    Mackie NE; Dunn DT; Dolling D; Garvey L; Harrison L; Fearnhill E; Tilston P; Sabin C; Geretti AM; ;
    AIDS; 2013 Sep; 27(14):2245-53. PubMed ID: 24157905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
    Fabian L; Taverna Porro M; Gómez N; Salvatori M; Turk G; Estrin D; Moglioni A
    Eur J Med Chem; 2020 Feb; 188():111987. PubMed ID: 31893549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H.
    Yang F; Yang J; Zhang Z; Tu G; Yao X; Xue W; Zhu F
    Curr Med Chem; 2022; 29(10):1664-1676. PubMed ID: 34238145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains.
    Suryawanshi R; Jadhav S; Makwana N; Desai D; Chaturbhuj D; Sonawani A; Idicula-Thomas S; Murugesan V; Katti SB; Tripathy S; Paranjape R; Kulkarni S
    Bioorg Chem; 2017 Apr; 71():211-218. PubMed ID: 28236450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H.
    Wang L; Sarafianos SG; Wang Z
    Acc Chem Res; 2020 Jan; 53(1):218-230. PubMed ID: 31880912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Cichero E; Fossa P
    J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small Conformational Changes Underlie Evolution of Resistance to NNRTI in HIV Reverse Transcriptase.
    Srivastava A; Birari V; Sinha S
    Biophys J; 2020 May; 118(10):2489-2501. PubMed ID: 32348721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological activity of sporolides A and B from Salinispora tropica: in silico target prediction using ligand-based pharmacophore mapping and in vitro activity validation on HIV-1 reverse transcriptase.
    Dineshkumar K; Aparna V; Madhuri KZ; Hopper W
    Chem Biol Drug Des; 2014 Mar; 83(3):350-61. PubMed ID: 24165098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations.
    Sörstedt E; Carlander C; Flamholc L; Hejdeman B; Svedhem V; Sönnerborg A; Gisslén M; Yilmaz A
    Int J Antimicrob Agents; 2018 May; 51(5):733-738. PubMed ID: 29371105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.
    Montes B; Segondy M
    J Med Virol; 2002 Mar; 66(3):299-303. PubMed ID: 11793380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
    Das K; Arnold E
    Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II).
    Cutinho PF; Shankar RC; Anand A; Roy J; Mehta CH; Nayak UY; Murahari M
    J Biomol Struct Dyn; 2020 Aug; 38(13):3772-3789. PubMed ID: 31526232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors.
    Amiel C; Desire N; Schneider V; Delphin N; Race E; Clavel F; Piolot T; Dam E; Rozenbaum W; Nicolas JC
    AIDS; 2005 Nov; 19(16):1922-4. PubMed ID: 16227805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Parrotta L; Perno CF; Svicher V
    Drug Resist Updat; 2011 Jun; 14(3):141-9. PubMed ID: 21295512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.